Filing summary: DelMar Pharmaceuticals, Inc. — Q3 2013 Form 10-Q
Entity note: The supplied filing is for DelMar Pharmaceuticals, Inc., not Tuhura Biosciences, Inc. It covers the quarter and nine months ended September 30, 2013; financial statements are unaudited and in U.S. dollars.
Business context and reporting period
DelMar is a development-stage biotechnology company focused on cancer drug development. Its lead candidate, VAL-083, is being studied in a Phase I/II trial for recurrent glioblastoma. The January 2013 reverse acquisition made DelMar (BC) the accounting acquirer. The company reported no product revenue and said it did not expect significant near-term revenue.
Key financial metrics
| Metric | Q3 / September 30, 2013 | Comparable period / prior balance |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Net result | Q3 net income of $6.79 million | Q3 2012 net loss of $427,825 |
| Nine-month net result | Net loss of $7.42 million | Nine-month 2012 net loss of $1.98 million |
| Operating expenses | Q3: R&D $560,235; G&A $741,368 | Q3 2012: R&D $229,488; G&A $218,732 |
| Nine-month expenses | R&D $1.78 million; G&A $3.32 million | Nine-month 2012: R&D $1.22 million; G&A $781,324 |
| Cash and liquidity | Cash $5.17 million; working capital $4.97 million | December 31, 2012: cash $17,782; working capital deficit $942,562 |
| Cash flows | Nine-month operating cash use $4.49 million; financing inflows $9.64 million | 2012 operating cash use $631,288; financing inflows $671,570 |
| Liabilities and equity | Derivative liability $4.79 million; stock-option liability $208,776; Valent loan $270,328; stockholders’ deficiency $304,295 | December 31, 2012 derivative liability $121,000; stockholders’ deficiency $1.33 million |
The Q3 profit was driven by an $8.09 million noncash gain from revaluing warrant-related derivative liabilities, not by operating revenue. For the nine months, the company recorded a $951,564 derivative revaluation gain, alongside $2.71 million of derivative issuance costs and a $598,000 expense for shares issued to Valent in exchange for reduced future royalties. The company reported no margins because it had no product revenue.
Material changes versus prior periods
- R&D and G&A increased substantially year over year. Management attributed R&D growth to clinical-trial activity, patient-enrollment timing, personnel, patent work and travel. G&A rose partly because of reverse-acquisition and public-company costs, professional fees, investor relations and stock-based compensation.
- The company raised $10.5 million gross in a 2013 private unit offering and reported approximately $8.575 million in net proceeds after offering costs. The financing materially improved cash and working capital.
- Common shares outstanding increased to 31.52 million at September 30 from 13.05 million at December 31, 2012. The 2013 offering issued 13.125 million units, each comprising one share and one five-year warrant; additional shares were issued in the reverse acquisition and for other purposes.
- The derivative liability rose from $121,000 to $4.79 million, with valuation changes materially affecting reported earnings. Management said share-price movements could cause significant future income-statement volatility.
Outlook, commentary and risks
- Management estimated that available funding would support operations for at least 18 months, based on its current estimates. It also said additional financing would be needed over the medium to longer term and may not be available on acceptable terms. Delays or cost overruns could require more funding or changes to development plans.
- The company planned to continue VAL-083 dose escalation in the GBM trial. It reported interim findings of no drug-related serious adverse events at doses studied, stable disease or tumor regression in some patients, and that the maximum tolerated dose had not yet been reached. These are preliminary clinical observations, not evidence of established efficacy.
- The FDA allowed a revised dose-escalation plan that skips two interim doses and permits escalation above 30 mg/m² if safety and tolerability allow. A third trial site opened at UCSF in July 2013.
- Management described potential China commercial opportunities for VAL-083, which is approved there for CML and lung cancer, but stated it was seeking a marketing partner. No payments had been made under the supply and collaboration agreement described in the filing.
- Key risks include clinical and regulatory uncertainty, lack of revenue, dependence on future financing, and intellectual-property protection concerns in China. The $4.79 million derivative liability uses Level 3 valuation inputs and management estimates.
- Subsequent commitment: an investor-relations consultant could receive up to 440,000 shares, including up to 240,000 scheduled monthly shares from October 2013 through March 2014 and a discretionary 200,000-share bonus.
Important facts for investors to verify
- Confirm the issuer identity: this filing names DelMar Pharmaceuticals, Inc., despite the request metadata naming Tuhura Biosciences, Inc.
- Review the derivative-liability valuation, warrant terms and the effect of future share-price changes on reported earnings.
- Assess the assumptions behind the stated 18-month cash runway, projected trial costs and need for additional financing.
- Check current status and subsequent results of the VAL-083 trial, including dose escalation, safety findings and regulatory plans.
- Review dilution exposure from outstanding warrants and options, including the 13.125 million investor warrants and placement-agent warrants.
- Examine related-party arrangements with Valent, including the loan, clinical-development payables and royalty-reduction transaction.